Renaissance Technologies (RenTech)'s INBX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 50,183 shares of Inhibrx Biosciences, Inc. (INBX) worth $3.37 M, representing 0.01% of the portfolio. First purchased in 2023-Q1, this short-term holding has been held for 8 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in INBX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 44,200 shares. Largest reduction occurred in Q2 2023, reducing 121,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Inhibrx Biosciences (INBX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Inhibrx Biosciences (INBX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -2,417 | Reduce 4.60% | 50,183 | $67.23 |
| Q4 2025 | +44,200 | Add 526.19% | 52,600 | $79.00 |
| Q3 2025 | +8,400 | New Buy | 8,400 | $33.68 |
| Q4 2024 | -25,100 | Sold Out | 0 | $0.00 |
| Q3 2024 | +25,100 | New Buy | 25,100 | $15.66 |
| Q3 2023 | -92,300 | Sold Out | 0 | $0.00 |
| Q2 2023 | -121,200 | Reduce 56.77% | 92,300 | $0.03 |
| Q1 2023 | +213,500 | New Buy | 213,500 | $0.02 |
Renaissance Technologies (RenTech)'s Inhibrx Biosciences Investment FAQs
Renaissance Technologies (RenTech) first purchased Inhibrx Biosciences, Inc. (INBX) in Q1 2023, acquiring 213,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Inhibrx Biosciences, Inc. (INBX) for 8 quarters since Q1 2023.
Renaissance Technologies (RenTech)'s largest addition to Inhibrx Biosciences, Inc. (INBX) was in Q1 2023, adding 213,500 shares worth $4,029.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 50,183 shares of Inhibrx Biosciences, Inc. (INBX), valued at approximately $3.37 M.
As of the Q1 2026 filing, Inhibrx Biosciences, Inc. (INBX) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Inhibrx Biosciences, Inc. (INBX) was 213,500 shares, as reported at the end of Q1 2023.